|
CDCA7 as a novel biomarker beside imaging to predict prognosis and tumor immunity in glioma patients
|
G. Zhu   , K. Chen , S. Yang , P. Feng , W. Fan , Y. Peng , J. Wei , X. Gao |
| Department of Neurosurgery, The Second Affiliated Hospital of Jiujiang University, Jiujiang, China , soar7974@163.com |
|
|
Abstract: (53 Views) |
Background: Cell division cycle-associated 7 (CDCA7) is implicated in tumor proliferation, but its clinical, immune, and imaging relevance in glioma remains incompletely defined. Materials and Methods: CDCA7 expression and prognostic value were evaluated using TCGA/GTEx, CGGA, GEO, and CCLE datasets. Immune-cell infiltration, immune checkpoints, and predicted immune-checkpoint blockade response were assessed using ssGSEA, TIMER, and TIDE. LinkedOmics-based co-expression, Gene Ontology, KEGG, and GSEA analyses were performed. Preoperative MRI features were analyzed in 286 patients with matched TCGA transcriptomic and TCIA imaging data, and radiomic features were evaluated in a subset of 85 patients. CDCA7 expression was validated in clinical tissues, and loss-of-function experiments were conducted in U251 and T98G cells. Results: CDCA7 was significantly overexpressed in glioma and increased with tumor grade. High CDCA7 expression was associated with poorer overall, disease-specific, and progression-free survival and showed strong diagnostic performance (AUC = 0.982). CDCA7-high tumors more frequently demonstrated contrast enhancement, necrosis, severe edema, multifocality, and larger contrast-enhancing volumes. After adjustment for age, IDH status, and histological grade, necrosis (adjusted OR = 2.32), contrast enhancement (adjusted OR = 1.85), and severe edema (adjusted OR = 2.45) remained independently associated with high CDCA7 expression. A five-feature radiomic model predicted CDCA7 status with an AUC of 0.76. CDCA7 expression correlated with immune infiltration and checkpoint molecules. CDCA7 knockdown reduced proliferation, migration, and invasion and increased sensitivity to temozolomide and cisplatin. Conclusion: CDCA7 is a prognostic, immune-related, and imaging-associated biomarker in glioma and may represent a potential therapeutic target. |
|
| Keywords: Glioma, magnetic resonance imaging, radiomics, CDCA7, prognosis. |
|
|
Full-Text [PDF 1215 kb]
(14 Downloads)
|
|
Type of Study: Original Research |
Subject:
Radiation Biology
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
